Clinical Trial Update: Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 safety data for Tinengotinib (TT-00420) as monotherapy in patients with advanced solid tumors and triple-negative breast cancer has been completed, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Tinengotinib (TT-00420) (tinengotinib)

Snippet

Sponsor: TransThera Sciences (Nanjing), Inc. | Conditions: Advanced Solid Tumors, Triple Negative Breast Cancer | Phase 1 | Status: COMPLETED